| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8679501 | Thrombosis Research | 2018 | 4 Pages |
Abstract
In the last years, several direct oral anticoagulants (DOACs) have emerged as alternatives to heparins and vitamin K antagonists for the treatment of VTE, but data regarding both efficacy and safety of DOACs in the subgroup of patients with cancer treatments were limited. The results of two studies evaluating the clinical benefit of treatment of VTE with direct oral anticoagulants in patients with cancer have been recently presented. Several studies comparing DOACs with LMWH are currently ongoing.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Melina Verso, Laura Franco, Michela Giustozzi, Cecilia Becattini, Giancarlo Agnelli,